Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 1
2004 2
2005 1
2006 1
2008 3
2009 2
2010 2
2011 5
2012 2
2013 4
2014 5
2015 1
2016 11
2017 6
2018 7
2019 4
2020 6
2021 8
2022 10
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for D. scit
Search for D. Sciti instead (1 results)
EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis.
Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, Halken S, Larenas-Linnemann D, Pawankar R, Pitsios C, Sheikh A, Worm M, Arasi S, Calderon MA, Cingi C, Dhami S, Fauquert JL, Hamelmann E, Hellings P, Jacobsen L, Knol EF, Lin SY, Maggina P, Mösges R, Oude Elberink JNG, Pajno GB, Pastorello EA, Penagos M, Rotiroti G, Schmidt-Weber CB, Timmermans F, Tsilochristou O, Varga EM, Wilkinson JN, Williams A, Zhang L, Agache I, Angier E, Fernandez-Rivas M, Jutel M, Lau S, van Ree R, Ryan D, Sturm GJ, Muraro A. Roberts G, et al. Allergy. 2018 Apr;73(4):765-798. doi: 10.1111/all.13317. Epub 2017 Oct 30. Allergy. 2018. PMID: 28940458
Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared …
Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have …
Effect of baseline serum vitamin D level on symptom and medication scores of subcutaneous immunotherapy in children with mite allergy.
Jia X, Zheng H, Yan X, Dai H, Xiang Q. Jia X, et al. Front Pediatr. 2022 Nov 1;10:1018549. doi: 10.3389/fped.2022.1018549. eCollection 2022. Front Pediatr. 2022. PMID: 36389357 Free PMC article.
In recent years, vitamin D levels have been speculated as a potential factor influencing SCIT efficacy. ...METHODS: According to the panel consensus, children with asthma and/or allergic rhinitis who received SCIT were divided into the vitamin D defici …
In recent years, vitamin D levels have been speculated as a potential factor influencing SCIT efficacy. ...METHODS: According …
Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite.
Baris S, Kiykim A, Ozen A, Tulunay A, Karakoc-Aydiner E, Barlan IB. Baris S, et al. Allergy. 2014 Feb;69(2):246-53. doi: 10.1111/all.12278. Epub 2013 Nov 4. Allergy. 2014. PMID: 24180595 Clinical Trial.
RESULTS: In the SCIT + vitamin D and SCIT alone groups, total asthma symptom score (TASS), total symptom score (TSS), and total medication scores (TMS) were significantly lower than pharmacotherapy group at the end of 1 year. ...Whereas the levels of Der p 1- …
RESULTS: In the SCIT + vitamin D and SCIT alone groups, total asthma symptom score (TASS), total symptom score (TSS), a …
Clinical aspects of sublingual immunotherapy tablets and drops.
Tankersley M, Han JK, Nolte H. Tankersley M, et al. Ann Allergy Asthma Immunol. 2020 Jun;124(6):573-582. doi: 10.1016/j.anai.2019.12.025. Epub 2020 Jan 7. Ann Allergy Asthma Immunol. 2020. PMID: 31923544 Review.
BACKGROUND: Sublingual immunotherapy (SLIT) is administered via tablets (SLIT-T) or liquid drops (SLIT-D). In North America, currently 4 SLIT-T formulations are approved by the US Food and Drug Administration for allergy immunotherapy, and SLIT-D is an off-label use …
BACKGROUND: Sublingual immunotherapy (SLIT) is administered via tablets (SLIT-T) or liquid drops (SLIT-D). In North America, currentl …
Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, Hering T, Huttegger I, Jung K, Klimek L, Kopp MV, Merk H, Rabe U, Saloga J, Schmid-Grendelmeier P, Schuster A, Schwerk N, Sitter H, Umpfenbach U, Wedi B, Wöhrl S, Worm M, Kleine-Tebbe J, Kaul S, Schwalfenberg A. Pfaar O, et al. Allergo J Int. 2014;23(8):282-319. doi: 10.1007/s40629-014-0032-2. Allergo J Int. 2014. PMID: 26120539 Free PMC article.
Severe, potentially life-threatening systemic reactions during SCIT are possible, but - providing all safety measures are adhered to - these events are very rare. ...Systemic reactions have been described in SLIT, but are seen far less often than with SCIT. In terms …
Severe, potentially life-threatening systemic reactions during SCIT are possible, but - providing all safety measures are adhered to …
Cluster protocols in SCIT: enough evidence for practical use?
Pfaar O, Leitzbach S, Hörmann K, Klimek L. Pfaar O, et al. Curr Opin Allergy Clin Immunol. 2010 Jun;10(3):188-93. doi: 10.1097/ACI.0b013e328339505c. Curr Opin Allergy Clin Immunol. 2010. PMID: 20410818 Review.
In accelerated cluster schedules two to three injections are administered sequentially per treatment day (with an interval of 30 min between the injections) in weekly intervals aimed to reach the maintenance dose of SCIT in a short time interval. Recent studies indicate th …
In accelerated cluster schedules two to three injections are administered sequentially per treatment day (with an interval of 30 min between …
Future directions in allergen immunotherapy.
Nelson HS. Nelson HS. Allergy Asthma Proc. 2022 Jul 1;43(4):356-362. doi: 10.2500/aap.2022.43.210098. Allergy Asthma Proc. 2022. PMID: 35818155
Despite this, many patients who could benefit from receiving SCIT and SLIT do not because of concerns about safety and the inconvenience in receiving SCIT, and the long duration of treatment with both, 3-4 years being required for lasting benefit. ...Those approache …
Despite this, many patients who could benefit from receiving SCIT and SLIT do not because of concerns about safety and the inconvenie …
Allergen immunotherapy now and in the future.
Nelson HS. Nelson HS. Allergy Asthma Proc. 2016 Jul;37(4):268-72. doi: 10.2500/aap.2016.37.3966. Allergy Asthma Proc. 2016. PMID: 27401313 Review.
BACKGROUND: Subcutaneous (SCIT) and sublingual (SLIT) immunotherapy provide effective treatment for allergic rhinitis and allergic asthma with clinical improvement following an adequate course of therapy persisting in most patients for years after treatment is discontinued …
BACKGROUND: Subcutaneous (SCIT) and sublingual (SLIT) immunotherapy provide effective treatment for allergic rhinitis and allergic as …
Perspectives in allergen immunotherapy: 2019 and beyond.
Pfaar O, Agache I, de Blay F, Bonini S, Chaker AM, Durham SR, Gawlik R, Hellings PW, Jutel M, Kleine-Tebbe J, Klimek L, Kopp MV, Nandy A, Rabin RL, van Ree R, Renz H, Roberts G, Salapatek AM, Schmidt-Weber CB, Shamji MH, Sturm GJ, Virchow JC, Wahn U, Willers C, Zieglmayer P, Akdis CA. Pfaar O, et al. Allergy. 2019 Dec;74 Suppl 108:3-25. doi: 10.1111/all.14077. Allergy. 2019. PMID: 31872476 Review.
Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets a …
Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progre …
Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling.
Batard T, Canonica WG, Pfaar O, Shamji MH, O'Hehir RE, van Zelm MC, Mascarell L. Batard T, et al. Mol Immunol. 2023 Mar;155:124-134. doi: 10.1016/j.molimm.2023.02.004. Epub 2023 Feb 16. Mol Immunol. 2023. PMID: 36806944 Review.
Allergy to house dust mites (HDM) is a perennial respiratory disease that affect more than half a billion people worldwide. Dermatophagoides pteronyssinus and D. farinae, two HDM species, are major sources of indoor allergens triggering allergic inflammation. ...In this ar …
Allergy to house dust mites (HDM) is a perennial respiratory disease that affect more than half a billion people worldwide. Dermatophagoides …
82 results